Immunomodulatory effects of silymarin in patients with β-thalassemia major

International Immunopharmacology

Volumn 16, Issue 2, 2013, Pages 243-247

  Gharagozloo, Marjan ^a,d   Karimi, Mehran ^b   Amirghofran, Zahra ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Cell mediated immunity; Cytokine; Immunomodulator; Lymphocyte; Silymarin; Thalassemia

Indexed keywords

COMPLEMENT; DEFEROXAMINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 4; NEOPTERIN; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TABLET; THALASSEMIA MAJOR; TREATMENT DURATION;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CELL PROLIFERATION; COMPLEMENT C3; COMPLEMENT C4; CYTOKINES; DEFEROXAMINE; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; LEUKOCYTES, MONONUCLEAR; MALE; NEOPTERIN; PHYTOHEMAGGLUTININS; SIDEROPHORES; SILYMARIN; YOUNG ADULT;

EID: 84877819990     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.04.016     Document Type: Article

References (34)

1. D. Rund, and E. Rachmilewitz Beta-thalassemia N Engl J Med 353 2005 1135 1146
2. J.P. Kushner, J.P. Porter, and N.F. Olivieri Secondary iron overload Hematology Am Soc Hematol Educ Program 1 2001 47 61
3. S. Cunningham-Rundles, P.J. Giardina, R.W. Grady, C. Califano, P. McKenzie, and M. De Sousa Effect of transfusional iron overload on immune response J Infect Dis 182 Suppl. 1 2000 S115 S121
4. U. Ezer, F. Gülderen, V.K. Culha, N. Akgül, and O. Gürbüz Immunological status of thalassemia syndrome Pediatr Hematol Oncol 19 2000 51 58 (Pubitemid 34665494)
5. B. Bagherpour, M. Gharagozloo, and B. Moayedi The influence of iron loading and iron chelation on the proliferation and telomerase activity of human peripheral blood mononuclear cells Iran J Immunol 6 2009 33 39
6. M. Gharagozloo, B. Bagherpour, M. Tahanian, F. Oreizy, Z. Amirghofran, and H.M. Sadeghi Premature senescence of T lymphocytes from patients with beta-thalassemia major Immunol Lett 29 122 2009 84 88
7. M. Gharagozloo, M. Karimi, and Z. Amirghofran Double-faced cell-mediated immunity in beta-thalassemia major: stimulated phenotype versus suppressed activity Ann Hematol 88 2009 21 27
8. E. Middleton Jr., C. Kandaswami, and T.C. Theoharides The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer Pharmacol Rev 52 2000 673 751
9. L. Mira, M.T. Fernandez, M. Santos, R. Rocha, M.H. Florencio, and K.R. Jennings Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity Free Radic Res 36 2002 1199 1208 (Pubitemid 35230240)
10. R. Gazak, D. Walterova, and V. Kren Silybin and silymarin - new and emerging applications in medicine Curr Med Chem 14 2007 315 338
11. C. Loguercio, and D. Festi Silybin and the liver: from basic research to clinical practice World J Gastroenterol 17 2011 2288 2301
12. C. Hutchinson, A. Bomford, and C.A. Geissler The iron-chelating potential of silybin in patients with hereditary haemochromatosis Eur J Clin Nutr 64 2010 1239 1241
13. J.M. Bares, J. Berger, J.E. Nelson, D.J. Messner, S. Schildt, and L.J. Standish Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C J Clin Gastroenterol 42 8 2008 Sep 937 944
14. M. Gharagozloo, B. Moayedi, M. Zakerinia, M. Hamidi, M. Karimi, and M. Maracy Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial Fundam Clin Pharmacol 23 2009 359 365
15. B. Moayedi, M. Gharagozloo, N. Esmaeil, M.R. Maracy, H. Hoorfar, and M. Jalaeikar A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine Eur J Haematol 90 2013 202 209
16. F. Fraschini, G. Demartini, and D. Esposti Pharmacology of silymarin Clin Drug Investig 22 2002 51 65 (Pubitemid 34151333)
17. C. Wilasrusmee, S. Kittur, G. Shah, J. Siddiqui, D. Bruch, and S. Wilasrusmee Immunostimulatory effect of Silybum marianum (milk thistle) extract Med Sci Monit 8 2002 BR439 BR443
18. F. Alidoost, M. Gharagozloo, B. Bagherpour, A. Jafarian, S.E. Sajjadi, and H. Hourfar Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients Int Immunopharmacol 6 2006 1305 1310 (Pubitemid 43868191)
19. I. Lang, K. Nekam, G. Deak, G. Muzes, R. Gonzales-Cabello, and P. Gergely Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers Ital J Gastroenterol 22 1990 283 287
20. D. Farmakis, A. Giakoumis, E. Polymeropoulos, and A. Aessopos Pathogenetic aspects of immune deficiency associated with beta-thalassemia Med Sci Monit 9 2003 RA19 RA22
21. R. Loebstein, I. Dalal, E. Nisbet-Brown, M. Berkovitch, N. Meydan, and D. Andrews Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone Br J Haematol 98 1997 597 600 (Pubitemid 27386538)
22. A. Berdowska, and K. Zwirska-Korczala Neopterin measurement in clinical diagnosis J Clin Pharm Ther 26 2001 319 329 (Pubitemid 32989554)
23. E.M. Walker Jr., and S.M. Walker Effects of iron overload on the immune system Ann Clin Lab Sci 30 2000 354.65
24. J. Féher, and G. Lengyel Silymarin in the prevention and treatment of liver diseases and primary liver cancer Curr Pharm Biotechnol 13 2012 210 217
25. Z. Dong, H. Wei, R. Sun, and Z. Tian The roles of innate immune cells in liver injury and regeneration Cell Mol Immunol 4 2007 241 252
26. J. Schümann, J. Prockl, A.K. Kiemer, A.M. Vollmar, R. Bang, and G. Tiegs Silibinin protects mice from T cell-dependent liver injury J Hepatol 39 2003 333 340 (Pubitemid 37070249)
27. M. Gharagozloo, E. Velardi, S. Bruscoli, M. Agostini, M. Di Sante, and V. Donato Silymarin suppress CD4 + T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production Pharmacol Res 61 2010 405 409
28. M. Gharagozloo, E.N. Javid, A. Rezaei, and K. Mousavizadeh Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases Basic Clin Pharmacol Toxicol 112 2013 251 256
29. P.L. Meroni, W. Barcellini, M.O. Borghi, A. Vismara, G. Ferraro, and D. Ciani Silybin inhibition of human T-lymphocyte activation Int J Tissue React 10 1988 177 181 (Pubitemid 19013349)
30. D. Lorenz, P.W. Lucker, W.H. Mennicke, and N. Wetzelsberger Pharmacokinetic studies with silymarin in human serum and bile Methods Find Exp Clin Pharmacol 6 1984 655 661 (Pubitemid 15217352)
31. M. Gharagozloo, and Z. Amirghofran Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells J Cancer Res Clin Oncol 133 2007 525 532 (Pubitemid 46955680)
32. N. Bowern, I.A. Ramshaw, P. Badenoch-Jones, and P.C. Doherty Effect of an iron-chelating agent on lymphocyte proliferation Aust J Exp Biol Med Sci 62 Pt 6 1984 743 754 (Pubitemid 15144568)
33. H.M. Lederman, A. Cohen, J.W. Lee, M.H. Freedman, and E.W. Gelfand Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation Blood 64 1984 748 753 (Pubitemid 14073498)
34. P. Carotenuto, O. Pontesilli, J.C. Cambier, and A.R. Hayward Desferoxamine blocks IL 2 receptor expression on human T lymphocytes J Immunol 136 1986 2342 2347 (Pubitemid 16136805)